Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Investigate the First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Next Previous
Trial Profile

A Study to Investigate the First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenzilumab (Primary)
  • Indications COVID 2019 infections; Pneumonia
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 01 Nov 2020 Results published in the Mayo Clinic Proceedings
  • 14 Sep 2020 Primary endpoint (Time to clinical improvement, with clinical improvement defined as at least a 2-point improvement in the 8-point ordinal scale) has been met according to the results published in the Mayo Clinic Proceedings.
  • 14 Sep 2020 Results published in the Mayo Clinic Proceedings

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top